RNA-144101

Phase 1Small molecule

MMark Kleinman

RNA-144101 is one of 33 small molecule programs targeting Geographic Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyActive, not recruiting

Geographic AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Empaveli

Apellis Pharmaceuticals

Phase 3

3 5

Cemdisiran

Tecfidera

1 7

Farxiga

AstraZeneca

Phase 2

1 8

Xylocaine

MMEDRx USA, Inc.

Phase 2

1 9

Rapamune

PPrism Pharmaceuticals

Phase 2

1 10

Glucophage

EMD Serono

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

Withdrawn·MMark Kleinman·Phase 1·NCT01093170

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RNA-144101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RNA-144101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RNA-144101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mark Kleinman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMark Kleinman

RNA-144101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Geographic Atrophy1 trial

References

Drug Info

Quick Facts

Related News